MET and central nervous system cancer: Another inhibitor of MET crizotinib is being studied in combination with temozolomide and radiotherapy for newly diagnosed GBM (NCT02270034) and with dasatinib in pediatric patients with diffuse intrinsic pontine glioma and high-grade glioma (NCT01644773) (74).